British pharma company GlaxoSmithKline plc. is expanding its company board and announced Laurie Glimcher as a non-executive director. Glimcher will join the board on 1 September.
German-Spanish biotech Sygnis AG has made changes to its management team and supervisory board. Heikki Lanckriet, who was previously Co-CEO, will become sole CEO of Sygnis and will also retain his role as Chief Scientific Officer.
AIM-listed Tiziana Life Sciences has a new head: The clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases appointed Kunwar Shailubhai Chief Executive Officer and Chief Scientific Officer.
Belgian biopharmaceutical company Ablynx named Markus L.E. Ewert Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead the Company’s business development and corporate strategy activities and become a member of the Executive Committee.
Rare disease drug developer Swedish Orphan Biovitrum AB (Sobi) has named Guido Oelkers as the companys new President and CEO. Oelkers, who holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London, joins from BSN Medical GmbH, where he held the position of CEO.
Dutch gene therapy developer uniQure has appointed Steven l. Zelenkofske as its Chief Medical Officer.
Contract development and manufacturing organisation Recipharm has appointed Shabbir Mostafa as Director, Business Management UK & Ireland. He will be responsible for supporting customers in the UK and Ireland and driving sales of Recipharms manufacturing services.
French vet-med maker Virbac has named Frédéric Jodogne as Corporate Industrial Operations director in early April. He is in charge of implementing, organizing and leading supply chain and industrial strategies of the Group.
Jan Holmgren, developer of the first effective oral cholera vaccine, has been awarded the 2017 Sabin Gold Medal for his pioneering contributions to oral vaccine research and mucosal immunology, and his leadership in the discovery of the world’s first effective oral cholera vaccine.
Pharmalink AB has hired Renee Aguiar-Lucander as Chief Executive Officer. She will lead the expansion and strategic development of the Swedish specialty pharmaceutical company following the clinical success of its orphan drug Nefecon.